Publications

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P
J Med Chem (2016), 59(7), 3392-408

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A
J Mol Cancer Ther. (2016),15(4), 628-39

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M, Fasolini M, Forte B, Galvani A, Isacchi A, Khvat A, Krasavin MY, Lupi R, Orsini P, Perego R, Pesenti E, Pezzetta D, Rainoldi S, Riccardi-Sirtori F, Scolaro A, Sola F, Zuccotto F, Felder ER, Donati D, Montagnoli A
J Med Chem (2015), 58(17), 6875-98

Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers
Dal Corso A, Caruso M, Belvisi L, Arosio D, Piarulli U, Albanese C, Gasparri F, Marsiglio A, Sola F, Troiani S, Valsasina B, Pignataro L, Donati D, Gennari C.
Chemistry (2015), 21(18), 6921-9

Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect
Pulici M, Traquandi G, Marchionni C, Modugno M, Lupi R, Amboldi N, Casale E, Colombo N, Corti L, Fasolini M, Gasparri F, Pastori W, Scolaro A, Donati D, Felder E, Galvani A, Isacchi A, Pesenti E, Ciomei M.
ChemMedChem (2015), 10(2), 276-95

In vivo preliminary investigations of the effects of the benzimidazole anthelmintic drug flubendazole on rat embryos and fetuses.
M. Longo, S. Zanoncelli, M. Messina, I. Scandale, C. Meckenzie, T. Geary, K. Marsch, D. Lindley, G. Mazué.
Reproductive Toxicology (2014), 49: 33-42

Tolerability and toxicological profile of pixantrone (Pixuvri)>®) in juvenile mice. Comparative study with doxorubicin.
M. Longo, P. Della Torre, C. Allievi, A. Morisetti, S. Al-Fayoumi, JW. Singer.
Reproductive Toxicology (2014), 46:20-30

Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors
Casale E, Amboldi N, Brasca MG, Caronni D, Colombo N, Dalvit C, Felder ER, Fogliatto G, Galvani A, Isacchi A, Polucci P, Riceputi L, Sola F, Visco C, Zuccotto F, Casuscelli F.
Bioorg Med Chem. (2014), 22(15), 4135-50

Validation of a homogeneous fluorescence quenching assay for the direct quantification of a heparin-like compound in human plasma
L. Nobili, M. Goegan, D. Pezzetta, S. Pace, P. Barbieri and A. Molinari
European Bioanalysis Forum, Barcelona, Spain
19-21 November 2014

An energy based model able to describe the effect of anticancer drugs on tumor growth and host body weight
N. Terranova, F. Del bene, M. Germani, M. Rocchetti and P. Magni
PAGE, Spain
June 10-13, 2014

SCYX-7158: Reproductive Toxicity Studies
Longo M, Messina M, Ghiglieri A, Launay D, Giannotti E.
EUROTOX, Edimburgh, UK
September 7-10
, 2014

Stable Labeled Internal Standards Preparation: a Crucial Step for the Quantitation of Biological Fluids. ACCELERA "Pick the best" Approach
Fontana E, Pignatti A.
Simposio AFI, Rimini, Italy
June 11-12
, 2014

Tissue Distribution and Elimination of [14C]-CHF6001 a novel Phosphodiesterase-4 Inhibitor
Ghiglieri A, Messina M, Cenacchi V, Brogin G, Puccini P.
European Society for Autoradiography, Barcelona, Spain
May
12-14, 2014

Carbon-14 labeled Tribendimidine, a broad-spectrum anthelmintic drug<
E. Fontana, A. Pignatti, A. Ghiglieri, R. Battaglia, F. Cinato, C. Wang, E. de Hostos
J. of Labelled Compounds and Radiopharmaceuticals (2013) 56:471-474

Predictive pharmacokinetic-pharmacodynamic mo- deling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts
Rocchetti M, Germani M, Del Bene F, Poggesi I, Magni P. Pesenti E, De Nicolao G.
Cancer Chemother Pharmacol (2013), 71:1147-1157

Effects of the benzimidazole anthelmintic drug flubendazole on rat embryos in vitro
Longo M. Zanoncelli S, Colombo PA, Harhay MO, Scandale I, Mackenzie C, Geary T, Madrill N, Mazuè G.
Reproductive Toxicology (2013), 36:78-87

9-Fluorenone-2-Carboxylic Acid as a Scaffold for Tubulin Interacting Compounds
Calogero F, Borrelli S, Speciale G, Christodoulou MS, Cartelli D, Ballinari D, Sola F, Albanese C, Ciavolella A, Passarella D, Cappelletti G, Pieraccini S, Sironi M
ChemPlusChem (2013), 78(7), 663–669

Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)
Brasca MG, Mantegani S, Amboldi N, Bindi S, Caronni D, Casale E, Ceccarelli W, Colombo N, De Ponti A, Donati D, Ermoli A, Fachin G, Felder ER, Ferguson RD, Fiorelli C, Guanci M, Isacchi A, Pesenti E, Polucci P, Riceputi L, Sola F, Visco C, Zuccotto F, Fogliatto G.
Bioorg Med Chem. (2013), 21(22), 7047-63

The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56(+) Acute Monoblastic Leukaemia.
Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, Cazzaniga G, Rambaldi A, Introna M, Pesenti E, Alzani R.
PLoS One. (2013), 8(3), e58424

Antitumor efficacy on glioma models of PHA-848125, a multikinase inhibitor able to cross the blood brain barrier
Albanese C, Alzani R, Amboldi N, Degrassi A, Festuccia C, Fiorentini F, Gravina GL, Mercurio C, Pastori W, Brasca MG, Pesenti E, Galvani A, Ciomei M
Br J Pharmacol. (2013), 169(1), 156-66

Self-emulsifying drug delivery systems /SEDDS) and nanosuspensions: new challenges in preclinical Phase
C. Ciocca, M. D'Angeli, V. Saibene,, C. Piutti, D. Pezzetta M
AFI, Rimini, Italy
June 11-14, 2013

A PK/PD model of tumor growth after administration of an anti-angiogenic agent given alone or in combination in xenograft mice
M. Germani, M. Rocchetti, F. Del Bene, N. Terranova, I. Poggesi, G. De Nicolao, P. Magni M
PAGE, Glasgow, Scotland
June 10-12, 2013

Reversible and time dependent CYP450 Inhibition: in vitro model with human hepatocytes
V.Saibene, L.Vignati, D. Pezzetta M
ADME & Predictive Toxicology, Barcelona, Spain
April 11-12, 2013

Preparation of a suitable Stable Labeled Internal Standard (SLIS) of NMS-P937
Cacchione G, Pignatti A, Fontana E.
19th Workshop of the Int Isotope Society, Bad Soden, Germany
September 26-27
, 2013

Flubendazole embryotoxicity in rat embryos and fetuses
Longo M, Zanoncelli S, Messina M, Scandale I.
ETS, Stresa, Italy
September
8-11, 2013

Local tolerance evaluation of fibrin and thrombin solution in a free-flap model in the juvenile Sprague_Dawley rat
MT Neri, F. Carù, E. Riccardi, A. YD Ali, B. Rosa, M. Scarpellini, M. Bacci, C. Guarnieri
EUROTOX, Interlaken, Switzerland
September 1-4, 2013

Toxicological profile and tolerability of pixantrone (Pixuvri) in newborn mice. Comparative study with doxorubicin (DOX)
Colombo P, Longo M, Della Torre P, Morisetti A, Allievi C, Singer J.
SOT, San Antonio Texas, USA
March 10-14
, 2013

Flubendazole embryotoxicity in rat embryos and fetuses
Colombo P, Longo M, Zanoncelli S, Messina M, Schnurbus R, Scandale I, Mazuè G.
SOT, San Antonio Texas, USA
March 10-14
, 2013

A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation
Germani M, Del Bene F, Rocchetti M, Van Der Graaf PH.
Computer Methods and Programs in Biomedicine (2012)

Piperaquine Phosphate: Reproduction studies
Longo M, Pace S, Messina m, Ferraris L, Brughera M, Ubben D, Mazuè G. M
Reproductive Toxicology (2012), 34:584-597

A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs
Magni P, Terranova N, Del Bene F, Germani M and De Nicolao G.
IEEE Transactions on Biomedical Engineering (2012), 59(8):2161-2170

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M, Scanziani E, Belotti D, Giavazzi R
Br J Cancer
(2012), 107(2), 360-369

NMS-P937, an orally available, specific, small molecule Polo-Like Kinase 1 inhibitor with antitumor activity in solid and haematological malignancies
Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J
Mol Cancer Ther.
(2012), 11(4), 1006-1016

Recommendations on bioanalytical method stability implications of co-administered and co-formulated drugs by Global CRO Council for Bioanalysis (GCC)
Lowes S, Boterman M, Doig M, Breda M et al.
Bioanalysis (2012) 4(17):2117-2126

Recommendations on ISR in multi-analyte assays, QA/Bioanalytical consultants and GCP by Global CRO Council for Bioanalysis (GCC)
Sangster T, Maltas J, Struwe P, Hillier J, Boterman M, Doig M, Breda M et al.
Bioanalysis (2012) 4(14):1723-1730

Recommendations on the interpretation of the new European Medicines Agencies Guideline on Bioanalytical Method Validation by Global CRO Council for Bioanalysis (GCC)<
Boterman M, Doig M, Breda M et al.
Bioanalysis (2012) 4(6):651-660

Development of an ELISA system for the specific quantification of the active form of a bi-specific biopharmaceutical new drug in plasma
Franco della Vedova, Antonio Molinari, Mara Goegan, Raphaela Schnurbus, Mathias Locher and Massimo Breda
European Bioanalysis Forum, Barcelona, Spain
14-16 November 2012

Quantitative determination of homocysteine in huyman plasma by LC-MS/MS using surrogate analyte approach
Simona Barattè, Francesca Scaroni and Massimo Breda
European Bioanalysis Forum, Barcelona, Spain
14-16 November 2012

Development and Validation of Bioassays for the Development of Biotherapeutics
Antonio Molinari, Pietro Grossi and Massimo Breda
ISSX, Noordwijk aan Zee, The Netherlands
17-21 June 2012

LAB Technologies for today ADME discovery
D. Pezzetta, L. Vignati, A. Moscone, D. Giribone, F. Cinato, C. Ciocca, M. D’Angeli, P. Grossi M
ADME & Predictive Toxicology, Munich, Germany
March 13-14, 2012

Whole Embryo Culture(WEC) assay to assess the embryotoxic potential of benzimidazole anthelmintics
Longo M, Colombo P, Zanoncelli S, Scandale I, Mazuè G. M
EUROTOX, Stockholm, Sweden
June 17-20, 2012

Use of Accurate Mass Spectrometry and NMR for Early Assessment of Cross-Species Metabolism
F. Cinato, D. Giribone, R. Battaglia, D. Pezzetta and P. Grossi M
ISSX, Noordwijk ann Zee, The Netherlands
June 17-21, 2012

Population pharmacokinetic analysis in healthy volunteers treated with different oral formulations of riluzole
F Del Bene, M. Germani, F. Fiorentini, M. Rocchetti, P. Bettica M
PAGE, Venice, Italy
June 5-8, 2012

Gingival Hyperplasia in Beagle Dog treated with Cyclosporine A
Colombo P, Arrigoni C, Riccardi E, Di Gallo G, Marchesi F, Giusti A
EUROTOX, Stockholm, Sweden
June 17-20, 2012

Minimizing Risk of Cross-contamination in Control Samples of Toxicology Studies
Colombo P, Neri MT, Breda M, Grossi P., Schnurbus R.
EUROTOX, Stockholm, Sweden
June 17-20, 2012

Accelera Isotope chemistry Team against "Murphy laws": a Case Study
Fontana E, Pignatti A, Cacchione G, Grossi P. Isola R.
IIS: 11th Int Symp on the Synthesis and applications of Isotopes and Isotopically Labelled Compounds, Heidelberg, Germany
September 9-13, 2012

Hematological Characterization of a Mouse Model for Myeloproliferative Disorders with JAK2 V6117F (C57BL/6JN2) Allele
AM. Giusti, U. Bonfanti, G. Texido, E. Pesenti, P. Colombo, P. Gnocchi, M. Germani
SOT, San Francisco, USA
March 11-15, 2012

In vitro and in vivo tools to assess the myelotoxicity of anti-cancer drugs
M. Prosser, F. Fiorentini, M. Germani, F. Del Bene, AM Giusti, G. Pennella
AACR-NCI-EORTC, Berlin, Germany
November 16-19, 2011

CHF 5074 a Novel y-Secretase Modulator for the Prevention and Treatment of Alzheimer's Desease: Stable and Radiolabelling Approaches
E.Fontana, A.Pignatti, F.Pivetti, BP.Imbimbo
18th Workshop of the International Isotope Society, Bad Soden, Germany
22-23 September, 2011

Spontaneous Hematopoietic Tumors in Control Sprague Dawley Rats: Six Cases
F. Marchesi, E. Riccardi, AM Giusti
Joint meeting ESTP ESVP/ECVP, Uppsala, Sweden
07-10 September, 2011

Diagnostic Value of Cytologic Evaluation of Tumors and Tumor-like Conditions of the oral Cavity in Dogs and Cats: A Prospective Case Study on 114 Cases
U. Bonfanti, W. Bertazzolo, M. Gracis, G. Romanelli, P. Roccabianca, G. Avallone, E. Zini
11th ESVCP-ECVCP Meeting, Dublin, Ireland
31 August - 03 September, 2011

Hematologic Abnormalities in VAV-JAK2V617F (C57BI/6J N2) Transgenic Mice
U. Bonfanti, G. Texido, W. Veronelli, E. Pesenti, P. Gnocchi, AM Giusti, M. Germani
11th ESVCP-ECVCP Meeting, Dublin, Ireland
31 August - 03 September, 2011

An Effective way to deliver drugs at the endotracheal/endobronchial level in the cynomolgus monkey
P. Colombo, F. Carù, B. Rosa, U. Bonfanti, R. Schnurbus
Eurotox, Paris, France
29-31 August, 2011

Use of combination of in vivo and in vitro assays to assess the embryotoxic potential of artemisinins
P. Colombo, M. Longo, S. Zanoncelli, R. Schnurbus
Eurotox, Paris, France
29-31 August, 2011

A new population PK/PD model to assess the myelotoxicity of candidate drugs in preclinical and in clinical studies
F. Del Bene, N. Terranova, F. Fiorentini, M. Germani, P. Magni
Population Approach Group Europe (PAGE)
Athens, Greece. 7-10 June 2011

The 3rd Global CRO Council for Bioanalysis at the International Reid Bioanalytical Forum
Breda M, Garofolo F, Caturla MC et al.
Bioanalysis (2011) 3,24:2721-2727

Synthesis of 2H- and 14C-labeled fexinidazole and its primary metabolites labeled with 2H
Erminia Fontana, Alberto Pignatti, Serena Venegoni, Michael A. Bray
J. of Labelled Compounds and Radiopharmaceuticals (2011) 54:714-719

Predicting Myelosuppression of Drugs from in Silico Models
Patrizia Crivori, Giulia Pennella, Miriam Magistrelli, Pietro Grossi and AnnaMaria Giusti
J. of Chemical Information and Modeling (2011), 51,434-445

Safety Pharmacology
Arrigoni Claudio and Perego Valeria
in: John Wiley & Sons, Inc. - Editor: A. Lodola and J. Stadler: “Pharmaceutical Toxicology in Practise: A Guide for Non-Clinical Development” (2011), Chapter 5:51-82

The Regulatory Environment
Claudio Bernardi and Marco Brughera
in:John Wiley & Sons, Inc. - Editor: A. Lodola and J. Stadler: “Pharmaceutical Toxicology in Practise: A Guide non Non-Clinical Development" (2011), - Chapter 2: 09-18

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor
Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B
Bioorg Med Chem Lett.
(2011) 21(10), 2969-2974.

Direct Detection of Heparin Derivates in Human Plasma: a Comparison of Several Bioassay Approaches
Antonio Molinari, Liliana Nobili, Miriam Magistrelli, Massimo Breda and Pietro Grossi
European Bioanalysis Forum, Barcelona
16-18 November 2011

Cross-Contamination in control samples of Toxicology studies: the Role of Bioanalysis
Massimo Breda, Simona Barattè, Enrico Frigerio, Paolo Colombo and Pietro Grossi
European Bioanalysis Forum, Barcelona
16-18 November 2011

Development of Automated Methodology for Metabolite Identification
F. Cinato, D. Giribone, D. Pezzetta, P.Grossi, G. Cruciani, I. Zamora, F. Fontaine M
ADMET, Munich, Germany
March 28-29, 2011

Application of in vivo and in vitro tools for detection of embryotoxicity: the example of artemisinin-type compounds
P. Colombo, M. Longo, S. Zanoncelli, R. Schnurbus, P. Grossi M
50th Annual Meeting SOT, Washington DC, USA
March 6-10, 2011

A non parametric population approach for selecting biomarkers of a drug action
N. Terranova, F. Del Bene, F. Fiorentini, P. Magni, M. Germani M
Population Approach Group Europe (PAGE)
Athens, 7-10 June 2011

Non-human primates models: their value, and the current EU perspective on 3Rs (SCHER report)
Claudio Bernardi M
Proceedings of the 11th FELASA Symposium, New Paradigms in Laboratory Animal Science (2010), 65-71

International Recommendations for Training Future Toxicologic Pathologists Participating in Regulatory-type, Nonclinical Toxicity Studies
Bolon B, Barale-Thomas E, Bradley A, Ettlin RA, Franchi CAS, George C, Giusti AM, Hall R, Jacobsen M, Konishi Y, Ledieu D, Morton D, Park JH, Scudamore CL, Tsuda H, Vijayasarathi SK, Wijnands MVW. M
Toxicologic Pathology (2010), 38(6):984-992

Cardiovascular Liabilities of Drugs: Regulatory Aspects
Arrigoni Claudio in: M
John Wiley & Sons, Ltd. “Cardiotoxicity of Non-Cardiovascular Drugs” (2010), Chapter 2: 25-47

Comparative embryotoxicity of different antimalarial peroxides: In vitro study using the rat whole embryo culture model (WEC)
Longo M, Zanoncelli S, Brughera M, Colombo P, Wittlin S, Vennerstrom JL, Moehrle J, Craft JC.
Reproductive Toxicology, (2010), 30:583-590

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy
Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, Festuccia C, Fiorentini F, Locatelli G, Pastori W, Patton V, Roletto F, Colotta F, Galvani A, Isacchi A, Moll J, Pesenti E, Mercurio C, Ciomei M
Mol Cancer Ther
(2010), 2243-2254

Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity
Bindi S, Fancelli D, Alli C, Berta D, Bertrand JA, Cameron AD, Cappella P, Carpinelli P, Cervi G, Croci V, D'Anello M, Forte B, Giorgini ML, Marsiglio A, Moll J, Pesenti E, Pittalà V, Pulici M, Riccardi-Sirtori F, Roletto F, Soncini C et al
Bioorg Med Chem.
(2010), 7113-7120.

4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors
Beria I, Valsasina B, Brasca MG, Ceccarelli W, Colombo M, Cribioli S, Fachin G, Ferguson RD, Fiorentini F, Gianellini LM, Giorgini ML, Moll JK, Posteri H, Pezzetta D, Roletto F, Sola F, Tesei D, Caruso M.
Bioorg Med Chem Lett.
(2010), 6489-6494

Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase
Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, Pesenti E, Galvani A, Isacchi A, Colotta F, Donati D, Moll J.
Cancer Res.
(2010), 10255-10264

Phosphorylation of TCTP as a Marker for Polo-like Kinase-1 Activity In Vivo
Cucchi U, Gianellini LM, DE Ponti A, Sola F, Alzani R, Patton V, Pezzoni A, Troiani S, Saccardo MB, Rizzi S, Giorgini ML, Cappella P, Beria I, Valsasina B.
Anticancer Res.
(2010) 30(12), 4973-4985

Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engrafment and high-burden leukemia models
Alzani R, Pedrini O, Albanese C, Ceruti R, Casolaro A, Patton V, Colotta F, Rambaldi A, Introna M, Pesenti E, Ciomei M, Golay J
Experimental Hematology
(2010) 38, 259-269

Efficacy of PHA-848125, a Cyclin Dependent Kinase inhibitor, on the K-RasG12DLA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging
Degrassi A, Russo M, Nanni C, Patton V, Alzani R, Giusti A, Fanti S, Ciomei M, Pesenti E, Texido G
Mol Cancer Ther
(2010) 9(3), 673-681

Optimisation of 6,6-Dimethyl Pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a Potent CDK Inhibitor Suitable for Intravenous Dosing
Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, Bischoff J, Borghi D, Casale E, Croci V, Fiorentini F, Isacchi A, Mercurio C, Nesi M, Orsini P, Pastori W, Pesenti E, Pevarello P, Roussel P, Varasi M, Volpi D, Vulpetti A, Ciomei M
Bioorganic & Medicical Chemistry
(2010) 18, 1844-1853

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the Cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study
Locatelli G, Bosotti R, Ciomei M, Brasca G,Calogero R, Mercurio C, Fiorentini F, Bertolotti M, Scacheri E, Scaburri A, Pesenti E, De Baere T, Soria JC, Lazar V, Isacchi A.
Mol Cancer Ther
(2010) 9(5), 1265-1273

Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Plk1 Inhibitors
Beria I, Ballinari D, Bertrand J, Borghi D, Bossi RT, Brasca MG, Cappella P, Caruso M, Ceccarelli W, Ciavolella A, Cinziani C, Croci V, DePonti A, Fachin G, Fergusson RD, Lansen J, Moll JK, Pesenti E, Posteri H, Perego R, Rocchetti M, Storici P et a
J. Med. Chem.
(2010) 53, 3532-3551

A review of analytical method for the determination of 5-fluorouracil in biological matrices
Breda M, Barattè S.
Analytical & Bioanalytical Chemistry (2010), 397:1191-1201

Development of an homogeneous sandwich immunoassay for the qualification of a PEGylated bio-pharmaceutical product in mouse plasma
Franco Della Vedova, Massimo Breda, Piero Grossi, Piero Trabucco*, Sarah David*
European Bioanalysis Forum, Barcelona
1-3 December 2010

Application of Dried Blood Spot Technique to HPLC-MS/MS Quantitative Bioanalysis of Naproxen in a Pharmacokinetic Study in Rats
G. Basileo, E. Frigerio, F. Gallazzi, C. Cavazzoli, P. Colombo, P.Grossi and M. Breda
European Bioanalysis Forum, Barcelona
1-3 December 2010

In vitro an in vivo tools to assess the myelotoxicity of anti-cancer drugs
M. Prosser, F. Fiorentini, M. Germani, F. Del Bene, AM Giusti, G. Pennella
EORTC_NCI-AACR, Berlin, Germany
November 16-19, 2010

VEGF Inhibitors toxicity in preclinical safety studies – an overview
Giusti AM, Della Torre P, Marchesi F, Pulci R, Parazzoli A, Giannotti E, Colombo P, Brughera M.
ESTP Congress, Budapest, Hungary
28 September-01 October, 2010

iagnostic Accuracy of cytologic Exdamination of Canine and Feline Mediastinal Masses: Retrospective study on 55 Cases
U. Bonfanti, W.Bertazzolo, L. Pintore, ME Gelain, E.Bottero
ECVIM-CA Congress, Tousouse, France
09-11 September, 2010

Target Organ Toxicity Induced by VEGF Inhibitors
AM. Giust, F. Marchesi, P. Della Torre, R. Pulci, A. Parazzoli, E. Giannotti, P. Colombo, M. Brughera
IUTOX, Barcelona, Spain
19-23 Luglio, 2010

Hematology and serum chemistry parameters in juvenile cynomolgus monkeys (Macaca fascicularis) of Mauritius origin: comparison between purpose-bred and captured animals
Bonfanti U, Lamparelli D, Colombo P, Bernardi C. M
J. Med Primatology (2009), 38:228-235.

CORRESPONDENCE: Antitumor efficacy testing in rodents.
Poggesi I, De Nicolao G, Germani M, Rocchetti M.
Journal of the National Cancer Institute, 2009, vol 101(22)

Testing Additivity of Anticancer Agents in Pre-Clinical Studies: A PK/PD Modeling Approach
Rocchetti M,
Del Bene F, Germani M, Fiorentini F, Poggesi I, Pesenti E, Magni P, De Nicolao G.
European J. of Pharmacology, 2009, 45:3336-3346

A model-based approach to the in vitro evaluation of anticancer activity
Del Bene F, Germani M, De Nicolao G, Magni P, Re CE, Ballinari D, Rocchetti M.
Cancer Chemother & Pharmacol (2009), 63(5):827-836

Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach
Rocchetti M, DelBene F, Germani M, Fiorentini F, Poggeti I, Pesenti E, Magni P, DeNicolao G
Eur J of Cancer
(2009) 45, 3336-3346

Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships
Ermoli A, Bargiotti A, Brasca MG, Ciavolella A, Colombo N, Fachin G, Isacchi A, Menichincheri M, Molinari A, Montagnoli A, Pillan A, Rainoldi S, Sirtori FR, Sola F, Thieffine S, Tibolla M, Valsasina B, Volpi D, Santocanale C, Vanotti E
Journal of Medicinal Chemistry
(2009) 52(14), 4380-4390

Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease
Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, Caprera F, Stortini G, Scanziani E, Pesenti E, Alzani R
Histology and Histopathology
(2009) 24(7), 879-891

Quantitative Glycoform Profiling by LC-MS/MS
Chiara Baroglio, Massimo Breda and Pietro Grossi
European Bioanalysis Forum, Barcelona
2-4 December 2009

Incurred Sample Reproducibility Evaluation: Practical Experience During the Application of Bioanalytical Methods for the Quantitation of Naproxen and Naproxcinod in Clinical Studies
S. Barattè, R. Pisano, G. Basileo, M. Mameli, E. Frigerio, P. Tocchetti*, M. Breda, P. Grossi
European Bioanalysis Forum, Barcelona
2-4 December 2009

47-Quantitative Glycoform Profiling by LC-MS/MS
C. Baroglio, M. Breda, P. Grossi
3rd Annual European Bioanalysis Forum, Barcelona, Spain
December 2-4, 2009

Incurred Sample Reproducibility Evaluation: Practical Experience during the Application of Bioanalytical Methods for the Quantitation of Naproxen and Naproxcinod in Clinical Studies
S. Barattè, R. Pisano, G. Basileo, M. Mameli, E. Frigerio, P. Tocchetti, M. Breda, P. Grossi
3rd Annual European Bioanalysis Forum, Barcelona, Spain
December 2-4, 2009

A4S: a user-friendly PKPK simulation software for non experts
Massimiliano Germani, Francesca Del Bene, Maurizio Rocchetti, Dave Fairman, Balaji M. Agoram & Piet H. van der Graaf
PAGE, San Pietroburgo - une 23-27, 2009

A Physiologically-Based Mathematical Model Software Package to Predict Lung Retention and Inhaled Pharmacokinetics of Therapeutic Candidates
Balaji M. Agoram, Massimiliano Germani, Maurizio Rocchetti, Francesca Del Bene, Rhys Jones and Piet van der Graaf
PAGE , San Pietroburgo - June 23-27, 2009

In Vitro Tools to Assess the Myelotoxicity of Kinase Inhibitors
M. Brughera, G. Pennella, M. Magistrelli, P. Rossi, A.M Giusti
SOT, Baltimore, March 15-19, 2009

CYP 450 Dependent Bioactivation of Xenobiotics into Toxic Metabolites: An In Vitro Approach
P. Grossi, L. Vignati, A. Moscone, D. Pezzetta, M. Brughera
SOT, Baltimore, March 15-19, 2009

The ART approach to drug discovery
Pietro Grossi, Daniele Pezzetta
ADMET, Berlin23-25 Feb, 2009

Model-Based Drug Development: a critical path opportunity. A case study of in vitro modeling in Oncology
Massimiliano Germani, Francesca Del Bene, Pietro Grossi, Maurizio Rocchetti
ADMET Europe, Berlino23-25 February, 2009

Cytological Aspects and Histological Correlation of Epithelial Odontogenic Tumors without Odontogenic Mesenchyme in Canine Species
U. Bonfanti, W. Bertazzolo, M. Gracis, S. Ferro
11th ESVCP-ECVCP Meeting, Thessaloniki, Greece
07-09 October, 2009

Evaluation of Stability of Rat EDTA Blood Samples stored at different Conditions
U. Bonfanti, M. Rocchetti, AM. Giusti, P. Colombo
11th ESVCP-ECVCP Meeting, Thessaloniki, Greece
07-09 October, 2009

Radiolabelled Compounds: a Powerful Tool for Dermal Absorption Assessment
A. Ghiglieri, E. Cozzi, L. Bigini, M. Messina, D. Giribone, E. Fontana
10th Int Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, Chicago, USA
14-18 June, 2009

Nemorubicin: an unusual anthracycline with low cardiotoxicity
P. Della Torre, R. Pulci, A.M. Giusti, A. Galvani, M. Ciomei, P. Colombo
AACR 100th Annual Meeting, Denver, USA
April 18-22, 2009

Best Practice for Incurred Samples Reproducibility Bioanalysis in Preclinical Studies
M. Prosser, S. Grassi, M. Mameli, S. Barattè, M. Breda, M. Brughera
SOT, Baltimore - March 2009

Haematology and Serum Chemistry Parameters in Cynomolgus Monkeys (Macaca Fascicularis): Comparison between Prupose-Bred and Captured Animals
P. Colombo, U. Bonfanti, D. Lamparellli C. Bernardi
SOT, Baltimore, March 2009


The Intracardiac ECG: an effective improvement in large animal cardiovascular assessment?

Carù F., Anelli M, Rosa B, Perego V, Cavazzoli C, Bonfanti U, Guglielmini C, Colombo P, Arrigoni C. M
Proceedings of the Tenth FELASA Symposiun 2007, Laboratory Animals, ISBN 978-1-85315-844-5, (2008) 133-137

Non clinical Safety Evaluation of Subibinib: A Potential Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors
Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, Denlinger R, Turnquist SE and Evering W. M
Toxicol Pathol (2008), 36:905-916

Synthesis of exemestane labelled with 13C
Fontana E., Pignatti A, Giribone D, DiSalle E M
Steroids 73-760:764, 2008

Syntheses of (R,S)-naproxen and its 6-O-desmethylated metabolite labelled with 2H
Fontana E, Venegoni S.
J of Labelled Compounds Radiopharm (2008), 51:239-241

Optimising experimental procedures using modeling approach in pharmacology: an example of application to oncology
Rocchetti M, Germani M, Del BeneF, Fiorentini F, Pesenti E, Croci V, Magni P, De Nicolao G.
Proceedings of the Tenth FELASA Symposiun 2007, Laboratory Animals, ISBN 978-1-85315-844-5, (2008) 65-70

Investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) using the Frog Embryo Teratogenesis Assay-Xenopus (FETAX)
Longo M, Zanoncelli S, Della Torre P, Rosa F, Riflettuto M, Giusti AM, Colombo P, Brughera M, Mazuè G, Olliaro P.
Reproductive Tox. (2008), 25:433-441

A Minimal Model of Tumor Growth Inhibition
Magni P, Germani M, De Nicolao G, Bianchini G, Simeoni M, Poggesi I, Rocchetti M.
IEEE Transactions on Biomedical Engineering (2008), 55(12):2683-2690

Computational models for P-Glycoprotein substrates and Inhibitors
Crivori P
“Methods and Principles in Medicinal Chemistry. Antitargets. Prediction and Prevention of Drug Side Effects”. edited by Roy J. Vaz and Thomas Klabunde, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. (2008), Chapter 16, Vol 38, pag.367-397

High-content analysis of kinase activity in cells
Gasparri F, Sola F, Bandiera T, Moll J, Galvani A
Combinatorial Chemistry & High Throughput Screening
(2008) 11, 523-536

A Ccd7 kinase inhibitor restricts initiation of DNA replication ad has antitumor activity
Montagnoli A, Valsasina B, Menichincheri M, Croci V, Tibolla M, Tenca PL, Rainoldi S, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Bensimon A, Vanotti E, Santocanale C
Nature Chemical Biology
(2008) 4 (6), 357-365

Development and validation of an inductively coupled plasma mass spectrometry method with optimized microwave-assisted sample digestion for the determination of platinum at ultratrace levels in plasma and ultrafiltrate plasma
M. Breda, M. Maffini, A. Mangia, C. Mucchino, and M. Musci
J. Pharm. Biomed. Anal. (2008), 48:435-439

Quantitative Assays of Peptides by LC-MS: Challenges to the Bioanalyst
Breda M, Grossi P. M
American Assoc. of Pharmaceutical Scientists (AAPS) - National Biotechnology Conference, Toronto, Canada
22-25 June 2008

Risk Associated to Study Samples Bioanalysis Using LC-MS/MS Methods
S. Barattè, E. Frigerio, S. Grassi, V. Preatoni, M Breda
25th LC/MS Montreaux Symp of the IAEAC, Montreaux, CH
November 12-14, 2008

Use of LC-MS for Quantitative Analysis in Preclinical Formulations
R. Pisano, M. Volpato, S. Barattè and M. Breda
25th LC/MS Montreaux Symp of the IAEAC, Montreaux, CH
November 12-14, 2008

Embryotoxicity of Artemisinin-Type Compounds
Longo M, Zanoncelli S, Colombo PA, Brughera M, Mazuè G, Olliaro P
37th Annual Meeting of the European Teratology Society (ETS), Edinburgh, UK
September 21-24, 2008

Mechanistic Approach to Study the Hematological Effect of PLK1 Inhibitors in Different Animal Species
Pennella G, Magistrelli M, Rossi P, Valsasina B, Beria I, Giusti AM
15th International Congress on In Vitro Toxicology, Stockholm, Sweden
September 25-28, 2008

35-Use of a Rapid Metabolite Profiling integrated with high-Giribone
Giribone D, Cinato F, Battaglia R, Pezzetta D, Grossi P
DMDG Open Meeting, Nottingham (UK)
September 17th - 19th, 2008

Evaluating the Influence of Different Sources of Variability in the PK/PD Tumor Growth Inhibition Model
Del Bene F, Germani M, Fiorentini F, De Nicolao G, Magni P, Rocchetti M.
17th meeting on Population Approach Group in Europe (PAGE), Marseille, France
June 18-20, 2008

”Cocktail” Incubation and Fast LC-MS/MS for CYP Inbibition Screening
Martignoni M, Vanoli L, Pezzetta D.
10 Eur. Regional Meeting – Int. Society for the study of Xenobiotics (ISSX), Vienna, Austria
18-21 May, 2008

Evaluation of compound re-precipitation from salt solution formulation: A Novel Screening Tool for Discovery Support
Ciocca C, D’Angeli M, Bozic R, Pezzetta D.
6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (APGI), Barcelona, Spain
07-10 April, 2008

Efficacy a Mechanism of Action-based Biomarkers: from Assay Development to Clinical Data
Castoldi R, Magistrelli M, Pulci R, Giusti AM, Brughera M.
EUFEPS-Development of Safe Protein Therapeutics: Preclinical, Clinical and Regulatory Issues, Munich, Germany
10-11 March, 2008

Non-clinical Development of Anticancer Drugs: Safety Considerations
Colombo P, Cattoni M, Di Gallo G, Pulci R, Brughera M
Eurotox, Rodi, Greece
October 5-8, 2008

Haematology and Serum Chemistry Parameters in Cynomolgus Monkeys (Macaca Fascicularis): Comparison between Purpose-Bred and Captured Animals
Bonfanti U, Lamparelli D, Colombo P, Bernardi C.
ESVCP & ISACP Congress 2008, Barcelona, Spain
Sept 30 - Oct 3, 2008

Morphological and Functional Changes of Exocrine Pancreas Injury in Cynomologus Monkeys Treated with a Cyclin Dependent Kinase Inhibitor
Giusti Anna Maria, Rondena Marco, Lamparelli Domenica, Marchesi Francesco, Roccabianca Paola, Brughera Marco
Society of Toxicologic Pathology – 27th Annual Symposium, San Francisco, USA
June 22-26, 2008

Nonparametric Modeling and Population Approach to the Individualized Heart Rate Correction of the QT Interval
Germani M, Russu A, Greco G, De Nicolao G, Del Bene F,Fiorentini F, Arrrigoni C, Rocchetti M.
17th meeting on Population Approach Group in Europe (PAGE), Marseille, France
June 18-20, 2008

A sensitive, Simple and Robust Analytical Method for the Determination of Levocetirezine in Human Plasma by LC-MS-MS Following Plasma Protein Precipitation
Frigerio E, Basileo G, Breda M.
19th Int.Symposium on Pharmaceutical & Biomedical Analysis (PBA), Gdansk, Poland
8-12 June, 2008

Incurred Samples Reproducibility – Practical Experience
Mucci B, Basileo G, Frigerio E, Barattè S, Breda M.
19th Int.Symposium on Pharmaceutical & Biomedical Analysis (PBA), Gdansk, Poland
8-12 June, 2008

Toxicology Considerations for Preclinical development of Anticancer Drugs
Colombo P, Cattoni M, Pulci R, Brughera M.
47th Annual Meeting SOT, Seattle, Washington, USA
16-20 March, 2008

Toxicity Assessment with Kinase Inhibitors
Giusti AM, Della Torre P, Castoldi R, Cattoni M, Brughera M.
47th Annual Meeting SOT, Seattle, Washington, USA
16-20 March, 2008

Synthesis of PHA-690509 labelled with 14C
Fontana E, Giribone D, Feliciti C. M
J of Labelled Compounds and Radiopharm (2007), 50:225-227

Assessment of QT Liabilities in Drug Development
Arrigoni C, Crivori P. M
Cell Biology and Toxicology (2007), 23(1):1-13

Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems
Crivori P, Morelli A, Pezzetta D, Rocchetti M, Poggesi I.
Eur J Pharm Sci. (2007), 32(3):169-181

Expression of Serine/Threonine Protein-Kinases and related Factors in Normal Monkey and Human Retinas: the Mechanistic Understanding of a CDK2 Inhibitor Induced Retinal Toxicity
Saturno G, Pesenti M, Cavazzoli C, Rossi A, Giusti AM, Gierke B, Pawlak M, Venturi M
Toxicol. Pathol. (2007). 35:972-983

Predicting the active doses in humans from animal studies: A novel approach in oncology
Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I
Eur. J. Can. (2007), 43(12), 1862-1868

Assessing and managing toxicities induced by kinase inhibitors
Castoldi RE, Pennella G, Saturno GS, Grossi P, Brughera M, Venturi M.
Current Opinion in Drug Discovery & Development, (2007), 10(1):53-7

Evaluation of a Physiological-Based Pharmacokinetic Modeling for Simulation of First Time in Animal Study
Germani M, Crivori P, Rocchetti M, Burton PS, Wilson AGE, Smith ME, Poggesi I M
European J. of Pharmaceutical Sciences (2007), 31:190-201

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, Pesenti E, Fancelli D, Moll J.
Mol Cancer Ther.
2007 6 (12):3158-68

Pyrazoles as efficient adenine-mimetic heterocycles for the discovery CDK inhibitors
Pevarello P, Vulpetti A
Inhibitors of cyclin-dependent kinases as anti-tumor agents (Book)
(2007) 15, 323-347

Cell-cycle inhibitor profiling by high-content analysis
Gasparri F, Ciavolella A, Galvani A
Advances in Molecular Oncology (Book)
(2007) 604, 137-148

Cross platform microarray analysis for robust identification of differentially expressed genes
Bosotti R, Locatelli G, Healy S, Scacheri E, Sartori L, Mercurio C, Calogero R and Isacchi A
BMC Bioinformatics
(2007) 8, S5

Magnetic Resonance Imaging and Histopathological Characterization of Prostate Tumors in TRAMP Mice as Model for Pre-Clinical Trials
De Grassi A, Russo M, Scanziani E, Giusti A, Ceruti R, Texido G, Pesenti E
The prostate
(2007) 67,396-404

Antitumor Activity of Edotecarin in Breast Carcinoma Models
Ciomei M, Croci V, Stellari F, Amboldi N, Giavarini R, Pesenti E
Cancer Chemotherapy and Pharmacology
(2007) 60, 2, 229-235

Cdc7 is an active kinase in human cancer cells undergoing replication stress
Tenca P, Brotherton D, Montagnoli A, Rainoldi S, Albanese C, Santocanale C
Journal of Biological Chemistry
(2007) 282(1), 208-215

Solubility and Permeability Profiling for Lead Optimization
Pezzetta D, Ciocca C; D’ Angeli M, Grossi P.
World Pharmaceutical Congress, Philadelphia, USA
11-13 June 2007

Target Kinase Profiling Database: a tool for the mechanistic assessment of potential toxicity findings and their human relevance
Venturi M, Saturno G, Radice D, Ukmar G.
46th Annual Meeting SOT, Charlotte, North Carolina, USA
25-29 March, 2007

Physiology-Based Pharmacokinetic (PB PK) modeling as tools for simulating plasma and tissue concentration-time curves of compounds considering different routes of administration to various animal species
Grossi P,Germani M, Del Bene F, Rocchetti M, Crivori P.<
46th Annual Meeting SOT, Charlotte, North Carolina, USA
25-29 March, 2007

In Vitro Predictive Myelotoxicity Assessment for Novel Oncology Drugs
Brughera M, Pennella G, Magistrelli M, Venturi M.
46th Annual Meeting SOT, Charlotte, North Carolina, USA
25-29 March, 2007

Computational Models Supporting Lead Optimization in Drug Discovery and Pre-Clinical Development
Germani M.
“Dottorato in Bioingegneria e Bioinformatica dell’Università di Pavia”, Pavia, Italy

Phisiology-based Pharmacokinetic (PBPK) Modeling for Discovery Drug Candidates
Germani M, Del Bene F, Crivori P, Rocchetti M.
DMDG, Nerviano, Italy
January, 2007

CYPs-dependent Bioactivation of Xenobiotics to Toxic Metabolites: an in Vitro Approach
Vignati L, Moscone A, Monshouwer M, Grossi P, Pezzetta D.
DMDG, Nerviano, Italy
January, 2007

Toxicity Assessment in the Discovery of New Anticancer Drugs
Cattoni M, Colombo P, Brughera P.
EUROTOX 2007, 44th Congress of the European Societies of Toxicology, Amsterdam, The Netherlands
7-10 October, 2007

Evaluation of Long Term Effects of an Intracardiac Implant for ECG Recording in Conscious Monkeys
Arrigoni C, Carù F, Bonfanti U, Guglielmini C, Cavazzoli C, Perego V, Rosa B.
Safety Pharmacology Society, 7th Annual Meeting, Edinburgh, Scotland
19-21 September, 2007

Sotalol as Positive Control for Ikr Block in HEK-293 Cells and for Qt Prolongation in Conscious Monkeys and Dogs
Perego V, Arrigoni C, Cavazzoli C.
Safety Pharmacology Society, 7th Annual Meeting, Edinburgh, Scotland
19-21 September, 2007

Heart Rate Correction of the QT interval: a Nonparametric Individualized Approach
Greco G, Russu A, Arrigoni C, Magni P, De Nicolao G, Rocchetti M.
Safety Pharmacology Society, 7th Annual Meeting, Edinburgh, Scotland
19-21 September, 2007

Developmental toxicity studies using continuous and intermittent intravenous infusion
Carù F, Anelli M, Rosa B, Fusi A, Longo M, Zanoncelli S, Colombo P.
FELASA-ICLAS 2007 Joint Meeting, Cernobbio, Como, Italy
10-14 June, 2007

Novel Compound: Evaluation of Plasma, Cerebral-Spinal Fluid and Brain levels following single oral administration to male Sprague Dawley rats
Parazzoli A, Grassi S, Fusi A, Pellizzoni C.
FELASA-ICLAS 2007 Joint Meeting, Cernobbio, Como, Italy
10-14 June, 2007

The Presence of Drug in Control Samples: Minimising Risk of Contamination in Toxicology Studies
Colombo P, Breda M, Fiorentini F, Grossi P, Brughera M.
46th Annual Meeting SOT, Charlotte, North Carolina, USA
25-29 March, 2007

In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos
Longo M, Zanoncelli S, Della Torre P, Riflettuto M, Cocco F, Pesenti M, Giusti AM, Colombo P, Brughera M, Mazuè Guy, Navaratman V, Gomes M, Olliaro P.
Reproductive Toxicology (2006), 22(4):797-810

Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro
Longo M, Zanoncelli S, Manera D, Brughera M, Colombo P, Lansen J, Mazuè G, Gomes M, Taylor WRJ, Olliaro P.
Reproductive Toxicology (2006), 21(1):83-93

A mathematical model to study the effects of drugs administration on tumor growth dynamics
Magni P, Simeoni M, Poggesi I, Rocchetti M, De Nicolao G.
Mathematical Biosciences (2006), 200(2), 127-151

Computational Models Supporting Lead Optimization in Drug Discovery
Burton P, Poggesi I, Germani M, Goodwin JT.
Springer Book on Lead Optimization, (2006) Chapter 9, pp. 195-220

An in vivo and in vitro comparison of CYP gene induction in mice using liver slices and quantitative RT-PCR
Martignoni M, de Kanter R, Grossi P, Saturno G, Barbaria E, Monshouwer M.
Toxicology In Vitro (2006), 20 (1):125:131

Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction
Martignoni M, Groothuis GMM, de Kanter R.
Expert Opinion on Drug Metabolism & Toxicology (2006), 2(6):875-894

Computational Models identifying Potential Pgp-substrates and Inhibitors
Crivori P, Reinach B, Pezzetta D, Poggesi I.
Molecular Pharmaceutics, 2006, 3(1):33-44

Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine
Martignoni M, Groothuis G, de Kanter R.
Drug Metabolism and Disposition (2006), 34(6):1041-1046

Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs
Crivori P, Poggesi I.
European J of Medicinal Chemistry (2006), 41(7):795-808

Empirical Validation of a Rat In Vitro Organ Slice Model as a Tool for In Vivo Clearance Prediction
de Graaf IAM, de Kanter R, de Jager MH, Camacho R, Langenkamp E, van de Kerkhof EG, Groothuis GMM.
Drug Metabolism and Disposition (2006), 34(4), 591-599

3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors
Pevarello P, Fancelli D, Vulpetti A, Amici R, Villa M, Pittalà V, Vianello P, Cameron A, Ciomei M, Mercurio C, Bischoff JR, Roletto F, Varasi M and Brasca MG
Bioorganic and Medicinal Chemistry Letters
(2006) 16, 1084-1090

1,4,5,6-Tetrahydropyrrolo [3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile
Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, Carpinelli P, Croci W, Forte B, Giorgini ML, Klapwijk J, Marsiglio A, Pesenti E, Rocchetti M, Roletto F, Severino D, Soncini C, Storici P, Tonani R,
J Med Chem
(2006) 49, 7247-7251

PHA-680632, a novel Aurora kinases inhibitor with potent anti-tumoral activity
Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R, Giorgini ML, Cappella P, Ballinari D, Sola F, Varasi M, Bravo R, Moll J
Clinical Cancer Research
(2006) 12(13), 4080-4089

Automated Liquid-Liquid Extraction in conjunction with Liquid Chromatography/Tandem Mass Spectrometry for Quantitative Determina-tion of Naproxen in Human Plasma
Grassi S, Barattè S, Breda M, Mucci B.
Montreux Symposium 2006, France
8-10 November 2006

Determination of BXL-628 in human plasma by LC-MS-MS following liquid/liquid and solid-phase extraction
Basileo G, Calderoni S, Frigerio E, Fonte G, Breda M and D’Ambrosio D.
17th International Mass Spectrometry Conference, Prague
27 Aug / 01 Sept, 2006

Pharmacokinetic-Pharmacodynamic (PK-PD) modelling of tumor growth inhibition in vivo: a useful tool in drug discovery and development
Germani M, Del Bene F, Fiorentini F, Rocchetti M, Pesenti E, Croci W.
EUFEPS CONFERENCE, Basel, Switzerland
29 Nov. / 01 Dec, 2006

Computational Models for Identifying Potential P-Glycoprotein Substrates and Inhibitors
rivori P, Reinach B, Pezzetta D, Rocchetti M.
Targeted Therapies in Cancer: Myth or Reality, Milan, Italy
4-5 September, 2006

Pharmacokinetic-pharmacodynamic (PK-PD) modelling of tumor growth inhibition in vivo: a useful tool in drug discovery
Germani M, Del Bene F, Fiorentini F, Pesenti E, Croci W, Rocchetti M.
Targeted Therapies in Cancer: Myth or Reality, Milan, Italy
4-5 September, 2006

In Vitro Predictive Myelotoxicity Assessment for Novel Oncology Drugs
Pennella G, Magistrelli M, Venturi M.
Targeted Therapies in Cancer: Myth or Reality, Milan, Italy
4-5 September, 2006

Mechanistic investigations to dissect cardiotoxicity and its putative link to inhibition of protein-kinase A
Saturno G, Castoldi R, Venturi M.
Targeted Therapies in Cancer: Myth or Reality, Milan, Italy
4-5 September, 2006

An in vitro approach to detect metabolite toxicity due to CYPs dependent bioactivation of xenobiotics
Vignati L, Moscone A, Grossi P, Pezzetta D.
9th European ISSX Meeting, Manchester, UK
4-7 June, 2006

Improvement In Rapid Metabolite Profiling Integrated with high throughput Metabolic Stability Assay
Cinato F, Battaglia R, Moscone A, Morelli A, Pezzetta D.
9th European ISSX Meeting, Manchester, UK
4-7 June, 2006

High Throughput Determination of Solubility of Active Hits
Bozic R, Pezzetta D.
When poor solubility Becomes an issue: From early stage to proof of principles, Verona, Italy
26-27 April 2006

Predicting clinically relevant myelotoxicity during pre-clinical trials after treatment with anti-cancer cell-cycle inhibitors: a biomarker approach
Saturno G, Magistrelli M, Castoldi R, Molinari F, Venturi M.
Clinical Biomarker Summit, San Diego, USA
29-31 March, 2006

In Vitro Mechanistic Screening to Reduce Attrition during Drug Development.
Magistrelli M, Pennella G, Venturi M.
SITOX meeting, Rome, Italy
February, 2006

A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies
de Kanter R, Tuin A, van de Kerkhof E, Martignoni M, Draaisma AL, de Jager MH, de Graaf IAM, Meijer DKF, Groothuis GMM.
J. of Pharmacological and Toxicological Methods (2005), 51(1):65-72

Virtual screening to enrich a compound collection with CDK2 inhibitors using docking, scoring, and composite scoring models
Cotesta S, Giordanetto F, Trosset J-Y, Crivori P, Kroemer RT, Stouten PFW, Vulpetti A.
Proteins: Structure, Function and Bioinformatics (2005), 60(4):629-643

Lack of Strain-Related Differences in Drug Metabolism and Efflux Transporter Characteristics between CD-1 and Athymic Nude Mice
Martignoni M, de Kanter R, Moscone A, Grossi P, Monshouwer M.
Cancer Chemotherapy and Pharmacology (2005), 55(2): 129-135

Structure-Based Approaches to Improve Selectivity: CDK2-GSK3b Binding Site Analysis
Vulpetti A, Crivori P, Cameron A, Bertrand J, Brasca MG, D'Alessio R, Pevarello P.
J. of Chemical Information and Modeling (2005), 45(5):1282-1290

Predictive model for identifying potential CYP2D6 inhibitors
Crivori P, Poggesi I.
Basic & Clinical Pharmacology & Toxicology (2005), 96(3):251-253

An in vitro approach for detecting the CYP3A4-dependent bioactivation of xenobiotics to toxic metabolites
Vignati L, Turlizzi E, Monaci S, Grossi P, de Kanter R, Monshouwer M.
Toxicology (2005), 216(2-3):154-167

Substrate Specific Metabolism by Polymorphic Cytochrome P450 2D6 Alleles
Bogni A, Monshouwer M, Moscone A, Hidestrand M, Ingelman-Sundberg M, Hartung T, Coecke S.
Toxicology in Vitro (2005), 19(5), 621-629

Evaluation of a physiologically-based pharmacokinetic approach for simulating the first-time-in-animal study
Germani M, Crivori P, Rocchetti M, Burton PS, Wilson AGE, Smith ME, Poggesi I.
Basic & Clinical Pharmacology & Toxicology (2005), 96(3):254-256

A predictive model for exemestane pharmacokinetics/pharmaco- dynamics incorporating the effect of food and formulation
Valle M, Di Salle E, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D.
British Journal of Clinical Pharmacology (2005), 59(3):355-364

A pharmacokinetic-pharmacodynamic model for predicting tumour growth inhibition in mice: a useful tool in oncology drug development
Rocchetti M, Poggesi I, Germani M, Fiorentini, Pellizzoni C, Zugnoni P, Pesenti E, Simeoni M, De Nicolao G.
Basic & Clinical Pharmacology & Toxicology (2005), 96(3):265-268

Traceless Solid-Phase Synthesis of 2-Amino-5-alkylidene-thiazol-4-ones
Pulici M, Quartieri F
Tetrahedron Letters
(2005) 46, 2387-2391

3-Aminopyrazole inhibitors of CDK2/cyclin A as Antitumor agents. 2. Lead Optimization
Pevarello P, Brasca MG, Orsini P, Traquandi G, Longo A, Nesi M, Orzi F, Piutti C, Sansonna P, Varasi M, Cameron A, Vulpetti A, Roletto F, Alzani R, Ciomei M, Albanese C, Pastori W, Marsiglio A, Pesenti E, Fiorentini F, Bischoff JR, Mercurio C
J Med Chem
(2005) 48, 2944-2956

Ion-suppression effects in liquid chromatography-tandem mass spectrometry due to a formulation agent, a case study in drug discovery bioanalysis
Larger PJ, Breda M, Fraier D, Hughes H, James CA.
J. of Pharmaceutical and Biomedical Analysis (2005), 39(1-2):206-216

Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues
Pisano R, Breda M, Grassi S, James CA.
J. of Pharmaceutical and Biomedical Analysis (2005), 38(4):738-745

A short review of analytical methods for the determination of estramustine phosphate and its metabolites in biological samples
Breda M, James CA.
Current Pharmaceutical Analysis (2005), 1(2):195-201

A multi column/dual solvent LC system to automatically screen methods for new compounds and increase flexibility in the discovery bioanalytical laboratory
Larger P, Cavanus S, Franzoni S, Breda M. M
16th International Bioanalytical Forum – Bioanalysis: Past, Present and Future, Guidford, UK
04-07 July, 2005

Automated protein precipitation in 96-well filtration plate in conjunction with liquid chromatography/tandem mass spectrometry for quantitative determination of ranitidine in rat plasma
Mucci B, Breda M, James CA, Basileo G.
HPLC 2005 – Stockholm, Sweden
26-30 June, 2005

Evaluation of three validated LC-MS-MS bioanalytical methods using “real-sample” QCs.
Barattè
S, Cordella P, Frigerio E, James CA. M
HPLC 2005, Stockholm, Sweden
26-30 June, 2005

Target Profiling of Kinases in Retina Ohotoreceptor Layer
Saturno G, Pesenti M, Cavazzoli C, Ferrari R, Klapwijk J, Rossi A.
EUROTOX, 42nd Congress of the European Societies of Toxicology, Cracow, Poland
11-15 September, 2005

Implementation of variability in a physiologically-based pharmacokinetic approach for simulating the first-in-animal study
Germani M, Simeoni M, Rocchetti M, Van der Graaf PH, Salhi S, Milligan P, Poggesi I.
PAGE 2005 (Population Approach Group Europe), 14th meeting, Pamplona, Spain
16-17 June, 2005

Counting events: population approaches using NONMEM
Simeoni M, Van Der Graaf PH, Milligan P, Verotta D, De Nicolao G, Rocchetti M, Poggesi I.
PAGE 2005 (Population Approach Group Europe), 14th meeting, Pamplona, Spain
16-17 June, 2005

Use of a basic PB-PK model for modeling pharmacokinetic data following different administration routes
Poggesi I.
PharmSciFair, Nice, France
12-17 June, 2005

In Silico Models for Predicting the Potential "Formulatability" Risk of Drug Candidates
Crivori P.
PharmSciFair, Nice, France
12-17 June, 2005

Synthesis of Stable Labeled Nemorubicin
Giribone D, Pignatti A, Fontana E.
13th Workshop of the International Isotope Society, Bad Soden, Germany
16-17 June, 2005

Decomposition of N-Oxide Metabolites in LC-MS-MS Bioanalysis: A Case Study for the Chiral Analysis of a New Anticancer Drug in Dog and Rat Plasma
Frigerio E, Sarati S, Cicioni C, Calderoli S, James CA. M
LC-MS, Montreux, France
10-12 November, 2004

Synthesis of estromustine, estramustine & estramustine phospate labelled with deuterium
Giribone D., Fontana E.
J.Label Compd Radiopharm 2004, 47:161:165

Labelled polymer supported drugs
Giribone D, Pignatti A, Fontana E.
Synthesis & Applications of Isotopically Label Compd (2004), 8:345-348. Proceedings of the International Symposium, 8th, Boston, MA, United States, June 1-5, 2003. Publisher: John Wiley & Sons Ltd., Chichester, UK

Microwaves: Applications to Isotope Labelled Compounds Preparatio
Giribone D., Felicini C., Pignatti A., Fontana E.
Synthesis & Applications of Isotopically Label Compd (2004), 8:341-344

Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents
Simeoni M, Magni P, Cammia C, De Nicolao G, Croci W, Pesenti E, Germani M, Poggesi I, Rocchetti M.
Cancer Research (2004), 64(3):1094-1101

Predicting Human Pharmacokinetics from Preclinical Data
Poggesi I.
Curr. Opin. Drug Discov. Devel. (2004), 7 (1):100-11

Prediction of Whole-Body Metabolic Clearance of Drugs through the Combined Use of Slices from Rat liver, Lung, Kidney, Small Intestine and Colon
De Kanter R, Monshouwer M, Draaisma AL, De Jager MH, De Graaf IAM, Proost JH, Meijer DKF, Groothuis GM.
Xenobiotica (2004), 34(3):229-241

A Human and Mouse Pregnane X Receptor Reporter Gene Assay in Combination with Cytotoxicity Measurements as a Tool to evaluate Species-Specific CYP3A Induction
Vignati L, Bogni A, Grossi P, Monshouwer M.
Toxicology (2004), 199(1):23-33

Phase I and Phase II Metabolic Activities are retained in Liver Slices from Mouse, Rat, Dog, Monkey and Human after Cryopreservation
Martignoni M, Monshouwer M, de Kanter R, Pezzetta D, Moscone A, Grossi P.
Toxicology in Vitro (2004), 18(1):121-128

HIGH-THROUGHPUT REAL-TIME PCR REACTION PREPARATION: Set-up of Automated Protocols Using the Biomek 2000
Barbaria E, Saturno G, Radice D.
Biomek Application Note Biorobotics. (2Q 2004)

Model Based on GRID-Derived Descriptors for estimating CYP3A4 Enzyme Stability of Potential Drug Candidates
Crivori P, Zamora I, Speed B, Orrenius C, Poggesi I.
J. Computer Aided-Molecular Design (2004), 183 (3):155-166

An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR
Martignoni M, de Kanter R, Grossi P, Mahnke A, Saturno G, Monshouwer M.
Chemico-Biological Interactions (2004), 151(1):1-11

Influence of Molecular Flexibility and Polar Surface Area Metrics on Oral Bioavailability in the Rat
Lu JJ, Crimin K, Goodwin, JT, Crivori P, Orrenius C, Xing L, Tandler PJ, Vidmar TJ, Amore BM, Wilson AGE, Stouten PFW, Burton PS.
Journal of Medicinal Chemistry, (2004), 47(24), 6104-6107

The death domain protein p84N5, but not the short isoform p84N5s, is cell cycle-regulated and shuttles between the nucleus and the cytoplasm
Gasparri F, Sola F, Locatelli G, Muzio M.
FEBS Letters
(2004) 574, 13-19

Sequence and structural analysis of kinase ATP pocket residues
Vulpetti A, Bosotti R
Il Farmaco
(2004) 10, 759-765

Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells
Montagnoli A, Tenca P, Sola F, Carpani D, Brotherton D, Albanese C, Santocanale C.
Cancer Research
(2004) 64, 7110-7116

In vivo Assessment of Antiangiogenic Activity of SU6668 in an Experimental Colon Carcinoma Model
Marzola P, Degrassi A, Calderan L, Farace P, Crescimanno C, Nicolato E, Giusti A, Pesenti E, Terron A, Sbarbati A, Abrams T, Murray L, Osculati F
Clinical Cancer Research
(2004) 10, 739-750

Analysis of Drugs and Metabolites in Tissues and Other Solid Matrices
James CA, Breda M, Barattè S, Casati M, Grassi S, Pellegatta B, Sarati S, Frigerio E.
Chromatographia (2004), 59:1-8

Quantitation of SU11248, an Oral Multi-Target Tyrosine Kinase Inhibitor, and its Metabolite in Monkey Tissues by Liquid Chromatograph with Tandem Mass Spectrometry following Semi-Automated Liquid-Liquid Extraction
Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q. M
J. of Chromatography, A (2004), 1024(1-2):87-94

The Effects of Degree of Hepatic and Renal Impairment on the Pharmacokinetic of Exemestane in Postmenauposal Women
Jannuzzo MG, Pogessi I, Spinelli R, Rocchetti M, Cicioni P, Buchan P. M
Cancer Chemother. Pharmacol. (2004) March 11

Bioanalytical Validation: A Risk-Based Approach?
James CA, Breda M, Frigerio E. M
J. Pharmaceutical and Biomedical Analysis (2004), 35:887-893

Simultaneous determination of estramustine phosphate and its four metabolites in human plasma by liquid chromatography-ionspray mass spectrometry
Breda M, Basileo, James CA. M
Biomedical Chromatography, (2004) 18:293-301

Comparison of protein precipitation, turbulent flow and automated on-line solid phase extraction, as plasma sample preparation techniques for the determination of compound I by LC-MS-MS
Calderoli S, Frigerio E, James CA. M
Chromatographia Supplement (2004) 59:S149-156

Safety Markers Identification and Bridging Assay Development
Venturi M, Barbaria EM, Castoldi R, ColzaniM, MoscaM.
The Conference on Toxicity Biomarkers, Philadelphia, USA
15-18 November, 2004

Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Tumor Growth Inhibition in Mice: a Magnetic Resonance Imaging Study
Rocchetti M, De Grassi A, Simeoni M, Pesenti E, Russo M, Poggesi I.
EORTC-NCI-AACR 16th Symposium, Geneva, Switzerland
28 Sept / 01 October, 2004

Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Tumor Growth Inhibition in Mice: the Activity of Brostallicin is enhanced in Cells with High Glutathione-S-Transferase
Germani M, Rocchetti M, Simeoni M, Del Bene F, Pesenti E, Geroni C, Colombo T, Marchini S, Poggesi I.
EORTC-NCI-AACR 16th Symposium, Geneva, Switzerland
28 Sept / 01 October, 2004

PK-PD Modeling of Tumor Growth Inhibition in Vivo
Rocchetti M, Poggesi I, Germani M, Fiorentini F, Pellizzoni C, Zugnoni P, Pesenti E, Simeoni M, De Nicolao G.
ISC Int. Conf, Florence, Italy
19-11 February, 2004

A PK-PD Model for Predicting Tumor Growth Inhibition in Mice: A useful tool in Oncology Drug Development
Rocchetti M, Poggesi I, Germani M, Fiorentini F, Pellizzoni C, Zugnoni P, Pesenti E, Simeoni
“In Silico Driven Drug Discovery and Development”, Geneva, Switzerland
26-28 May, 2004

Population Modeling of Tumor Growth in Untreated Xenografted Mice
Poggesi I, Simeoni M, Germani M, De Nicolao G, Rocchetti M
17-18 June, 2004

Predictive Modeling of tumor growth inhibition in vivo: Its Application to Anticancer Drug Development
Rocchetti M, Poggesi I, Germani M, Croci W, Pesenti E, Simeoni M, Cammia C, De Nicolao G.
AACR, Washington, USA
11-14 July, 2004